In addition to the expansion in Springdale, Ohio, the company plans to enhance its corporate headquarters in Evendale, Ohio. Both facilities, nearby one another, sit just outside of Cincinnati.
Enable Injections plans for its new 90,000-square-foot manufacturing center to support ongoing in-house manufacturing and supply of its enFuse medicine delivery technology. The company develops the enFuse platform, which allows hands-free, hidden needle drug delivery of up to 25 mL. Its simple design enables flexibility for at-home self-administration or in-clinic use.
The FDA cleared the system for the delivery of Empaveli in October. Enable Injections says it’s the first-ever hands-free wearable technology that allows patients to self-administer large-volume medications subcutaneously without an IV or syringe pump.
According to a news release, Enable Injections expects to begin occupying the new manufacturing facility by the end of 2024. As it becomes operational, the new location and the headquarters will retain and add more than 450 jobs over the next 10 years. Enable plans to renovate and enhance the infrastructure of the Evendale headquarters.
“Scalable, in-house manufacturing is a key pillar of Enable’s strategy to accelerate supply of our innovative enFuse technology as the company continues to grow our roster and scope of clinical and commercial engagements with pharmaceutical partners. This new facility allows Enable to significantly expand and enhance production processes and ultimately reduce the time it takes to bring our enFuse system to patients and the medical community,” said Mike Hooven, chair and CEO of Enable Injections. “We are proud to have grown our business in Ohio over the last decade and are thankful for the continued support from the state and local organizations as we expand our business operations and footprint.”
